CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the effectiveness of two host-directed therapies for patients with rifampicin-resistant tuberculosis. By conducting a multi-center trial, it aims to improve treatment outcomes and reduce long-term lung damage associated with this severe form of tuberculosis.
Tuberculosis is a leading cause of morbidity and mortality worldwide.
Current TB treatments are inadequate, requiring patients closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated.
These concerns are greatly magnified in rifampicin-resistant (RIF-R) TB, an urgent global and EU public health priority. WHO estimates that only 54% of patients who began RIF-R TB treatment in 2016 were cured.
In addition to these well-recognized shortcomings, current TB treatments,…
SWISS TPH SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE
SCHWEIZERISCHES TROPEN UND PUBLIC HEALTH INSTITUT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, MUNCHEN
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
South Africa, Isando
Type: Research institute
Activity type: Research Organisations
SME: No
Belgium, Antwerpen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Georgia, Tbilisi
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
